SAR 50.0
(2.46%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 685.96 Thousand SAR | -65.95% |
2022 | 2.01 Million SAR | -6.87% |
2021 | 2.16 Million SAR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 5064.00 SAR | 0.0% |
2024 Q1 | 5064.00 SAR | -87.28% |
2023 Q3 | 39.82 Thousand SAR | -86.86% |
2023 Q4 | 39.82 Thousand SAR | 0.0% |
2023 FY | 685.96 Thousand SAR | -65.95% |
2023 Q2 | 303.15 Thousand SAR | -0.0% |
2023 Q1 | 303.16 Thousand SAR | -57.73% |
2022 FY | 2.01 Million SAR | -6.87% |
2022 Q4 | 717.24 Thousand SAR | 0.0% |
2021 FY | 2.16 Million SAR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 65.82 Million SAR | 98.958% |
Al-Dawaa Medical Services Company | 329.22 Million SAR | 99.792% |
Nahdi Medical Company | 892.61 Million SAR | 99.923% |
Almujtama Alraida Medical Co. | 11.39 Million SAR | 93.979% |